Department moves into enhanced facility and increases headcount in response to continued demand for services
Quotient Clinical, a leading provider of early stage and specialist drug development services, has announced the expansion of its Data Sciences function with relocation to a larger office, staying in Edinburgh, UK.
The expansion comes in response to growing customer demand for the Data Sciences service. The total Data Sciences headcount has increased by more than 34% during the past 2 years and is now at more than 50 employees. Quotient Clinical is currently actively recruiting.
Quotient Clinical’s Data Sciences offering supports its proprietary Translational Pharmaceutics platform, which integrates formulation development, real-time adaptive GMP manufacturing and clinical testing.
The Data Sciences experts provide bespoke services for early phase clinical studies including: data management, eCRF programming, statistics and statistical programming, pharmacokinetic modelling and simulation, and medical writing.
These capabilities deliver real-time data to customers for review and interpretation, enabling crucial dosing decisions to be made during the course of a study and to aid development of clinical programmes post-study.
Greg Johnson, VP Data Sciences, Quotient Clinical, commented: 'Our unique Translational Pharmaceutics platform is increasingly being recognised in the industry for reducing clinical development timelines, cutting associated costs, and offering enhanced data-based decision making ability throughout the process. As a consequence, demand for our integrated Data Sciences service is also growing, and we are therefore delighted to announce this expansion and the move to a new larger office, ensuring that customers continue to receive the highest standard of service.'
Translational Pharmaceutics brings innovation to early drug development by integrating formulation development, real-time adaptive GMP manufacturing and clinical testing within a single organisation.
Drug products are manufactured in real-time immediately prior to clinical testing, creating the opportunity to modify dose and formulation compositions in response to emerging clinical data (safety, pharmacokinetic or pharmacodynamic). The platform can be applied to a wide range of drug products, including oral, inhaled, dermal and IV, and encompasses simple and complex formulation types.